Regulatory document
FDA determines 2013 labeling adequate to manage risk of retinal abnormalities, potential…
FDA Safety Communications · Information · USA · Jun 16, 2015
Key facts
| Title | FDA determines 2013 labeling adequate to manage risk of retinal abnormalities, potential vision loss, and skin discoloration with anti-seizure drug Potiga (ezogabine); requires additional study |
|---|---|
| Issuer | FDA Safety Communications |
| Source | FDA Safety Communications |
| Document type | Information |
| Country or region | USA |
| Date | Jun 16, 2015 |
| Document | fda.gov |
| Issuer website | fda.gov |
At a glance
- Yes Full text searchable in Orca1
- 100–999 Documents from this issuer in Orca1
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Global regulations and guidance
Regulations, guidance and official notices from medical device and medicines regulators worldwide, collected by Orca1 from each issuer's website. Only the title, issuer, date and link are shown here; the full text is searchable in Orca1.
Source: Medical device and medicines regulators and agencies as named on each record (EMA, MHRA, TGA, CDSCO, PMDA, NMPA, Health Canada, HSA, the FDA and others), collected by Orca1 from each issuer's website · Source date: